IMTX Immatics N.V.
Immatics N.V. (IMTX) is expected to report earnings on November 17, 2026, before the market open. The consensus earnings estimate is a loss of $0.57 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.4% since its last earnings release on August 18, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Immatics N.V.
Immatics N.V. engages in the discovery of targets for cancer immunotherapies. It is developing targeted immunotherapies with focus on treating solid tumors. Immatics N.V., formerly known as ARYA SCIENCES, is based in Tuebingen, Germany.
Sector
Healthcare
Industry
Biotechnology